Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $64.58 USD
Change Today +1.67 / 2.65%
Volume 928.9K
ALKS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

alkermes plc (ALKS) Key Developments

Alkermes Provides Update on FDA Review of ARISTADA for the Treatment of Schizophrenia

Alkermes plc announced that the U.S. Food and Drug Administration (FDA) has advised Alkermes that it will not be able to complete its review of the New Drug Application (NDA) for ARISTADA (aripiprazole lauroxil) for the treatment of schizophrenia by the Prescription Drug User Fee Act (PDUFA) action date of Aug. 22, 2015. The FDA indicated that this delay was expected to be brief, measured in terms of weeks, but could not confirm specific timing. The FDA also indicated that no additional data or information is required from Alkermes at this time.

Alkermes plc Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Year 2015

Alkermes plc reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $151,370,000 against $153,424,000 a year ago. Operating loss was $52,521,000 against $22,825,000 a year ago. Loss before income taxes was $43,045,000 against income before income taxes of $2,212,000 a year ago. Net loss was $46,109,000 against net income of $3,735,000 a year ago. Basic and diluted GAAP loss per share was $0.31 against basic and diluted non-gaap earnings of $0.02 a year ago. Basic and diluted non-gaap loss per share was $0.09 against diluted earnings per share of $0.11 a year ago. Non-GAAP net loss was $13,585,000 against non-GAAP net income of $17,722,000 a year ago. Capital expenditures were $14,046,000 against $5,753,000 a year ago. Free cash outflow was $27,631,000 against free cash inflow of $11,969,000 a year ago. For the six months, the company reported total revenues of $312,584,000 against $283,636,000 a year ago. Operating loss was $79,829,000 against $38,718,000 a year ago. Loss before income taxes was $73,192,000 against $18,376,000 a year ago. Net loss was $76,766,000 against $20,619,000 a year ago. Basic and diluted GAAP loss per share was $0.52 against $0.14 a year ago. Basic and diluted non-gaap loss per share was $0.03 against $0.22 a year ago. Non-GAAP net loss was $13,585,000 against non-GAAP net income of $17,722,000 a year ago. Capital expenditures were $14,046,000 against $5,753,000 a year ago. Free cash outflow was $27,631,000 against free cash inflow of $11,969,000 a year ago. Non-GAAP net loss was $4,428,000 against non-GAAP net income of $33,873,000 a year ago. Capital expenditures were $24,756,000 against $11,438,000 a year ago. Free cash outflow was $29,184,000 against free cash inflow of $22,435,000 a year ago. For the year 2015, the company expects net loss of $257.5 million or $1.72 net loss per share. Deferred revenue is expected to be $3.0 million. Projected non-gaap net loss is expected to be $57.0 million or $0.38 loss per share. Capital expenditures were expected to be $50.0 million. Projected free cash outflow is expected to be $107.0 million.

Alkermes plc to Report Q2, 2015 Results on Jul 30, 2015

Alkermes plc announced that they will report Q2, 2015 results at 8:30 AM, Eastern Daylight on Jul 30, 2015

Alkermes plc, Q2 2015 Earnings Call, Jul 30, 2015

Alkermes plc, Q2 2015 Earnings Call, Jul 30, 2015

Alkermes Not To Be Sold

Alkermes plc (NasdaqGS:ALKS) Chief Executive Officer said he is not interested in selling company. He thinks the company's research pipeline is attractive to potential buyers, but said "this is not the time when we're interested in being a seller."

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALKS:US $64.58 USD +1.67

ALKS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Depomed Inc $26.66 USD +0.04
Emergent BioSolutions Inc $32.49 USD -0.17
Impax Laboratories Inc $40.31 USD -0.58
Jazz Pharmaceuticals PLC $162.18 USD -2.07
Lupin Ltd 1,860 INR -2.75
View Industry Companies
 

Industry Analysis

ALKS

Industry Average

Valuation ALKS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.5x
Price/Book 6.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALKERMES PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.